Report Content
Chapter 1 Methodology & Scope
1.1 Methodology
1.2 Market scope & definitions
1.3 Base estimates and working
1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data sources
1.7.1 Primary
1.7.2 Secondary
1.7.2.1 Paid sources
1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Pet cancer therapeutics industry 360° synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Therapy trends
2.1.3 Route of administration trends
2.1.4 Species trends
2.1.5 Applications trends
2.1.6 Regional trends
Chapter 3 Pet Cancer Therapeutics Industry Insights
3.1 Industry landscape, 2018 - 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of pet cancer
3.2.1.2 Growing awareness among pet owners regarding pet diseases
3.2.1.3 Increasing pet care expenditure
3.2.1.4 Technological advancements in pet cancer therapeutics including cancer immunotherapy
3.2.1.5 High medical unmet need and strong potential
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects associated with pet cancer therapeutics
3.2.2.2 Lack of veterinary oncologists
3.3 Growth potential analysis
3.3.1 By therapy
3.3.2 By route of administration
3.3.3 By species
3.3.4 By application
3.4 COVID- 19 impact analysis
3.5 Product pipeline analysis
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 European Union
3.6.3 Brazil
3.6.4 Australia
3.6.5 India
3.7 Gap analysis
3.8 Porter's analysis
3.9 PESTLE analysis
Chapter 4 Competitive landscape, 2021
4.1 Introduction
4.2 Company matrix analysis, 2021
4.3 Competitive analysis of major market players
4.4 Competitive Positioning matrix
4.5 Strategy dashboard, 2021
Chapter 5 Pet Cancer Therapeutics Market, By Therapy
5.1 Key therapy trends
5.2 Chemotherapy
5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3 Immunotherapy
5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.4 Targeted therapy
5.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.5 Combination therapy
5.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 6 Pet Cancer Therapeutics Market, By Route of Administration
6.1 Key route of administration trends
6.2 Oral
6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3 Injection
6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 7 Pet Cancer Therapeutics Market, By Species
7.1 Key species trends
7.2 Dogs
7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.3 Cats
7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 8 Pet Cancer Therapeutics Market, By Application
8.1 Key application trends
8.2 Lymphoma
8.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.3 Mast cell cancer
8.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.4 Melanoma
8.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.5 Mammary and squamous cell cancer
8.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.6 Others
8.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 9 Pet Cancer Therapeutics Market, By Region
9.1 Key regional trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Sweden
9.3.7 Switzerland
9.3.8 The Netherlands
9.3.9 Austria
9.3.10 Poland
9.4 Asia Pacific
9.4.1 China
9.4.2 India
9.4.3 Japan
9.4.4 Australia
9.4.5 South Korea
9.4.6 Philippines
9.4.7 New Zealand
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
Chapter 10 Company Profiles
10.1 Zoetis, Inc.
10.2 Elanco Animal Health
10.3 Boehringer Ingelheim International GmbH
10.4 Dechra Pharmaceuticals
10.5 AB Science
10.6 Qbiotics
10.7 NovaVive, Inc.
10.8 ELIAS Animal Health
